Assessment of Data Sources That Support US Food and Drug Administration Medical Devices Safety Communications

被引:18
|
作者
Tau, Noam [1 ,2 ]
Shepshelovich, Daniel [3 ]
机构
[1] Sheba Med Ctr, Dept Diagnost Imaging, Ramat Gan, Israel
[2] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel
[3] Tel Aviv Sourasky Med Ctr, Div Internal Med, Tel Aviv, Israel
关键词
APPROVAL;
D O I
10.1001/jamainternmed.2020.3514
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Importance Medical Device Safety Communications (MDSCs) are used by the US Food and Drug Administration (FDA) to convey important new safety information to patients and health care professionals. The sources of initial safety signals that trigger MDSCs have not been described previously. Objective To assess the sources of initial safety signals that trigger publication of MDSCs and the potential associations among MDSC data source, type of safety issue, and subsequent FDA action. Design, Setting, and Participants In this cross-sectional study, all MDSCs published on the FDA website between January 1, 2011, and December 31, 2019, were assessed. The MDSC characteristics, sources of initiating safety signals, regulatory approval or clearance pathways of the related medical devices, and subsequent FDA actions were collected from the FDA website. Main Outcomes and Measures The main outcome was the distribution of sources of initial safety signals that led to publication of MDSCs. Secondary aims included exploration of potential associations among safety signal sources (direct reporting vs other), type of safety issue (death vs other), and FDA action (withdrawal vs other). Results A total of 93 MDSCs were evaluated. Median time from device approval to MDSC posting was 10 years (interquartile range, 6-16 years). The most common data sources that triggered MDSCs were direct reports to the FDA through the Medical Device Reporting (MDR) program (44 of 93 [47%]) followed by regulator-initiated assessments (32 [34%]). Common safety issues included patient injury (25 [27%]), potential wrong diagnoses (19 [20%]), and death (18 [19%]). Frequent FDA action after MDSC posting included recommendation for increased vigilance and caution (47 [51%]), complete device withdrawal (12 [13%]), and warnings of specific lots or clinics (12 [13%]). There was a statistically significant correlation between direct reports of adverse events to the FDA through the MDR program and risk of death as a safety issue (14 of 44 [32%] for direct reporting vs 4 of 49 [8%] for any other data sources,P = .007). Conclusions and Relevance In this cross-sectional study, the most common source of initial safety signals that triggered MDSCs was direct reports of real-world adverse events to the FDA through the MDR program. The delayed detection of postmarketing adverse events highlights the importance of proactive identification of emerging device-related safety issues. This cross-sectional study assesses the sources of initial safety signals that trigger publication of Medical Device Safety Communications and the potential associations among Medical Device Safety Communication data source, type of safety issue, and subsequent action by the US Food and Drug Administration. Question What are the sources of initial safety signals that trigger the US Food and Drug Administration's (FDA's) Medical Device Safety Communications? Findings Of the 93 Medical Device Safety Communications published between 2011 and 2019, the source of 47% was direct reports to the FDA through the Medical Device Reporting program, and 34% were initiated by regulator-initiated assessments. Safety communications triggered by direct reports were associated with risk of death as the safety issue. Meaning This study found that Medical Device Safety Communications were mainly triggered by direct reports to the FDA, highlighting the importance of proactive identification of device-related safety issues to improve patient safety.
引用
收藏
页码:1420 / 1426
页数:7
相关论文
共 50 条
  • [41] Exploratory Analyses of Efficacy Data From Schizophrenia Trials in Support of New Drug Applications Submitted to the US Food and Drug Administration
    Khin, Ni A.
    Chen, Yeh-Fong
    Yang, Yang
    Yang, Peiling
    Laughren, Thomas P.
    JOURNAL OF CLINICAL PSYCHIATRY, 2012, 73 (06) : 856 - 864
  • [42] EDUCATING NURSES ON THE ROLE OF THE FOOD AND DRUG ADMINISTRATION IN THE REGULATION OF MEDICAL DEVICES.
    Marin, Keith
    ONCOLOGY NURSING FORUM, 2017, 44 (02)
  • [43] The US Food and Drug Administration's Efforts to Support Ophthalmology Clinical Trials
    Eydelman, Malvina B.
    JAMA OPHTHALMOLOGY, 2014, 132 (12) : 1391 - 1392
  • [44] Food and drug administration control of medical devices - An inescapable intrusion and stimulus for adaptation
    Friedman, EA
    ASAIO JOURNAL, 1998, 44 (04) : 239 - 240
  • [45] Food and Drug Administration Regulation of Food Safety
    Stewart, Katie
    Gostin, Lawrence O.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 306 (01): : 88 - 89
  • [46] Surveying US Observational Data Sources and Characteristics for Drug Safety Needs
    Patrick Ryan
    Emily Welebob
    Abraham G. Hartzema
    Paul Stang
    J. Marc Overhage
    Pharmaceutical Medicine, 2010, 24 (4) : 231 - 238
  • [47] US Food and Drug Administration Updates
    Sahin, L.
    BIRTH DEFECTS RESEARCH, 2018, 110 (09): : 748 - 748
  • [48] Urokinase and the US food and drug administration
    Ouriel, K
    JOURNAL OF VASCULAR SURGERY, 1999, 30 (05) : 957 - 958
  • [49] Independence at the US Food and Drug Administration
    不详
    LANCET, 2006, 367 (9523): : 1630 - 1630
  • [50] Transparency at the US Food and Drug Administration
    Califf, Robert M.
    JOURNAL OF LAW MEDICINE & ETHICS, 2017, 45 : 24 - 28